Amiloride

• Description:

  Amiloride (MK-870) is an inhibitor of both epithelial sodium channel (ENaC[1]) and urokinase-type plasminogen activator receptor (uTPA[2]) . Amiloride is a blocker of polycystin-2 (PC2; TRPP2[3]) channel.

• Product Name Alternative:

  MK-870

• UNSPSC:

  12352005

• Hazard Statement:

  H301, H311, H331

• Target:

  Apoptosis; Sodium Channel; TRP Channel

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Membrane Transporter/Ion Channel; Neuronal Signaling

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Metabolic Disease; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/amiloride.html

• Concentration:

  10mM

• Purity:

  99.96

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=NC(Cl)=C(N)N=C1N)NC(N)=N

• Molecular Formula:

  C6H8ClN7O

• Molecular Weight:

  229.63

• Precautions:

  H301, H311, H331

• References & Citations:

  [1]Ji, H.L., et al. delta ENaC: a novel divergent amiloride-inhibitable sodium channel. Am J Physiol Lung Cell Mol Physiol, 2012. 303 (12) : p. L1013-26.|[2]Teiwes J, et al. Epithelial sodium channel inhibition in cardiovascular disease. A potential role for amiloride. Am J Hypertens. 2007 Jan;20 (1) :109-17.|[3]Giamarchi A, et al. A polycystin-2 (TRPP2) dimerization domain essential for the function of heteromeric polycystin complexes. EMBO J. 2010 Apr 7;29 (7) :1176-91.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Citation 01:

  ACS Nano. 2023 May 9;17 (9) :8141-8152.|Acta Biomater. 2025 Jul 1:201:171-186.|Adv Funct Mater. 2024 Oct 31.|Adv Funct Mater. 2025 Aug 3.|Adv Sci (Weinh) . 2024 Mar;11 (9) :e2307880.|Adv Sci (Weinh) . 2025 May 14:e2406150.|Am J Transl Res. 2021 Jul 15;13 (7) :7538-7555.|Anal Chem. 2025 Jun 17;97 (23) :12026-12034.|Biomaterials. 2026 Jan:324:123541.|Cell Commun Signal. 2023 May 4;21 (1) :99.|Cell Metab. 2022 Dec 6;34 (12) :2018-2035.e8.|Cell Mol Biol Lett. 2024 Dec 3;29 (1) :149.|Cell Physiol Biochem. 2018;51 (6) :2564-2574. |Cell Rep Med. 2025 Jul 15;6 (7) :102208.|Commun Biol. 2022 Nov 14;5 (1) :1248.|Environ Sci Technol. 2021 Mar 2;55 (5) :3144-3155.|FASEB J. 2025 Jan 15;39 (1) :e70298.|Int J Biol Macromol. 2024 Aug 5;277 (Pt 3) :134517.|J Am Chem Soc. 2018 Dec 12;140 (49) :17234-17240.|J Control Release. 2024 Oct 26:S0168-3659 (24) 00725-9.|J Control Release. 2025 Nov 20:389:114450.|J Hazard Mater. 2025 Dec 5:500:140498.|J Leukoc Biol. 2024 Jul 16:qiae159.|J Nanobiotechnology. 2020 Jan 31;18 (1) :26.|J Pharm Anal. 2025 Jul;15 (7) :101182.|J Pharm Biomed Anal. 2021 Feb 20:195:113870.|Mater Today Bio. 2025 Mar 27:32:101712.|Microb Pathog. 2019 Jul 18:103638. |Mol Neurodegener. 2025 Jul 23;20 (1) :84.|Mol Pharm. 2025 Apr 7;22 (4) :2182-2192.|Nanotechnology. 2018 Feb 23;29 (8) :085101.|Nat Biomed Eng. 2024 Nov;8 (11) :1469-1482.|Nat Nanotechnol. 2024 Dec;19 (12) :1903-1913.|Small Methods. 2021 Apr;5 (4) :e2001047.|Theranostics. 2019 May 31;9 (13) :3732-3753.|University of Toronto. 2025.|Acta Pharm Sin B. 2024 Dec;14 (12) :5418-5434.|Adv Sci (Weinh) . 2025 Apr 3:e2412356.|Biomaterials. 2022 May;284:121529.|Biosens Bioelectron. 2025 Jan 25:274:117184.|Br J Pharmacol. 2020 Aug;177 (15) :3473-3488. |Cell Mol Immunol. 2024 Aug;21 (8) :826-841.|Cell Rep. 2022 May 31;39 (9) :110880.|Food Chem. 2024 Sep 8;463 (Pt 1) :141196.|Int J Biol Macromol. 2022 May 15:207:559-569.|iScience. 2022 Oct 19;25 (12) :105403.|J Cell Biol. 2025 May 5;224 (5) :e202405060.|J Ethnopharmacol. 2022 Jun 28:292:115171.|J Neuroinflammation. 2022 Feb 22;19 (1) :53.|J Zhejiang Univ Sci B. 2025 May 28;26 (5) :461-476. |mBio. 2025 Mar 12;16 (3) :e0378724.|Res Sq. 2025 Nov 16.|Sci Total Environ. 2021 Jul 20:779:146523.|SSRN. 2025 Aug 21.|Theranostics. 2020 May 17;10 (15) :6581-6598. |Transl Res. 2024 Jan:263:53-72.

• CAS Number:

  2609-46-3